Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer

Lung Cancer

Volumn 73, Issue 1, 2011, Pages 103-109

  Takeda, Masayuki ^a   Okamoto, Isamu ^a   Hirabayashi, Naoko ^b   Kitano, Mami ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SRL INC   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Immunohistochemistry; Non small cell lung cancer; Predictive marker; S 1; Thymidylate synthase

Indexed keywords

CARBOPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OROTATE PHOSPHORIBOSYLTRANSFERASE; PACLITAXEL; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONIC ACID; PACLITAXEL; ROC CURVE; TEGAFUR; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79957713253     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.022     Document Type: Article

References (33)

1. Hoffman P.C., Mauer A.M., Vokes E.E. Lung cancer. Lancet 2000, 355:479-485.
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
3. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
4. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M.S., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13:2443-2449.
5. Reynolds C., Obasaju C., Schell M.J., Li X., Zheng Z., Boulware D., et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27:5808-5815.
6. Okamoto I., Nishimura T., Miyazaki M., Yoshioka H., Kubo A., Takeda K., et al. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505. Clin Cancer Res 2008, 14:5250-5254.
7. Tamura K., Okamoto I., Ozaki T., Kashii T., Takeda K., Kobayashi M., et al. Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Eur J Cancer 2009, 45:2132-2137.
8. Kaira K., Sunaga N., Yanagitani N., Imai H., Utsugi M., Shimizu Y., et al. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. Anticancer Drugs 2007, 18:471-476.
9. Kubota K., Sakai H., Yamamoto N., Kunitoh H., Nakagawa K., Takeda K., et al. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:702-706.
10. Okamoto I., Fukuoka M. S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2009, 10:290-294.
11. Maring J.G., Groen H.J., Wachters F.M., Uges D.R., de Vries E.G. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005, 5:226-243.
12. Zlobec I., Steele R., Terracciano L., Jass J.R., Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007, 60:1112-1116.
13. Zlobec I., Vuong T., Hayashi S., Haegert D., Tornillo L., Terracciano L., et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 2007, 96:793-800.
14. Danenberg P.V. Thymidylate synthetase-a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977, 473:73-92.
15. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995, 55:1407-1412.
16. Kirihara Y., Yamamoto W., Toge T., Nishiyama M. Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 1999, 14:551-556.
17. Fukushima M., Fujioka A., Uchida J., Nakagawa F., Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 2001, 37:1681-1687.
18. Copur S., Aiba K., Drake J.C., Allegra C.J., Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995, 49:1419-1426.
19. Matsuoka K., Tsukuda K., Suda M., Kobayashi K., Ota T., Okita A., et al. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil. Int J Oncol 2004, 24:217-222.
20. Nakano J., Huang C., Liu D., Masuya D., Nakashima T., Yokomise H., et al. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006, 95:607-615.
21. Huang C.L., Yokomise H., Kobayashi S., Fukushima M., Hitomi S., Wada H. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 2000, 17:47-54.
22. Miyoshi T., Kondo K., Toba H., Yoshida M., Fujino H., Kenzaki K., et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Anticancer Res 2007, 27:2641-2648.
23. Ichikawa W., Takahashi T., Suto K., Yamashita T., Nihei Z., Shirota Y., et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004, 91:1245-1250.
24. Ichikawa W., Takahashi T., Suto K., Shirota Y., Nihei Z., Shimizu M., et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 2006, 119:1927-1933.
25. Matsubara J., Nishina T., Yamada Y., Moriwaki T., Shimoda T., Kajiwara T., et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 2008, 98:832-839.
26. Beck A., Etienne M.C., Cheradame S., Fischel J.L., Formento P., Renee N., et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994, 30A:1517-1522.
27. Shintani Y., Ohta M., Hirabayashi H., Tanaka H., Iuchi K., Nakagawa K., et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer 2004, 45:189-196.
28. Nakagawa T., Tanaka F., Takata T., Matsuoka K., Miyahara R., Otake Y., et al. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with p-stage I nonsmall-cell lung cancer. J Surg Oncol 2002, 81:87-92.
29. Fukushima M., Morita M., Ikeda K., Nagayama S. Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med 2003, 12:839-844.
30. Suehisa H., Toyooka S., Hotta K., Uchida A., Soh J., Fujiwara Y., et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 2007, 25:3952-3957.
31. Okabe T., Okamoto I., Tsukioka S., Uchida J., Hatashita E., Yamada Y., et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 2009, 15:907-913.
32. Okabe T., Okamoto I., Tsukioka S., Uchida J., Iwasa T., Yoshida T., et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 2008, 7:599-606.
33. Takezawa K., Okamoto I., Tanizaki J., Kuwata K., Yamaguchi H., Fukuoka M., et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 2010, 9:1647-1656.